Life free of pain.
Our peptidomimetic transmembrane allosteric modulator of the mu opioid receptor offers a unique mechanism of action and has the potential to provide powerful pain relief without the downsides of traditional opioids.
Our peptidomimetic transmembrane allosteric modulator of the mu opioid receptor offers a unique mechanism of action and has the potential to provide powerful pain relief without the downsides of traditional opioids.
Our peptidomimetic transmembrane allosteric modulator of the mu opioid receptor offers a unique mechanism of action and has the potential to provide powerful pain relief without the downsides of traditional opioids. This cutting-edge technology is expected to have lower addiction and overdose risks and fewer adverse side effects, making it a safer option for chronic use. With our innovative approach, we aim to revolutionize the way we manage pain and improve the quality of life for patients.
This approach offers several advantages including lower risks of overdose and addiction, lower side effects, and the potential for safer chronic use. Our drug has the potential to be used as a companion drug to enhance existing therapies or reduce the dosage of other opioids in combined therapies, and could expand the customer base for opioid-based treatments. This novel approach to drug design provides a unique solution to the challenges posed by traditional opioid treatments.
The opioid pandemic is a major issue, with increasing numbers of people becoming addicted to painkillers and suffering from the negative consequences of their use. The current state of pain management is in need of a change. That's where mu42 comes in. With our innovative analgetic drug candidate, we aim to revolutionize the way pain is managed. Our unique mechanism of action offers improved safety and reduced side effects compared to traditional opioids, making it a safer and more effective solution for those in need of pain relief. At mu42, we are dedicated to improving the lives of those affected by pain, and we believe that our drug is the answer they have been searching for. We are changing the game in pain management, one life at a time.
The study of the molecular details of the opioid receptor's interaction with other membrane proteins and membrane components led to the creation of a unique, first-of-its-kind molecular skeleton of the drug candidate.
Thanks to the team's experience in modeling large, flexible, and dynamic biomolecular systems using large-scale computational biology and theoretical biophysics methods, the team conducted a structure optimization and developed preliminary candidates.
Concurrently, in vitro studies using molecular biology methods were conducted to verify in silico hypotheses and provided data inputs that allowed us to make significant progress in the drug design process.
In order to streamline the drug design and reconstruction process based on experimental data collected during the process, we also utilized advanced machine learning-based tools from our trusted partners.
Peptides are an exciting class of drug candidates that offer a unique combination of benefits from both small molecule and biotherapeutic realms. With relatively large contact surface areas with the target, peptides tend to exhibit high selectivity, resulting in fewer side effects and lower toxicity compared to other classes of drugs. Furthermore, the natural role of peptides as mediators of protein-protein interactions, highly selective receptor ligands, and allosteric modulators provides further evidence for their potential as effective therapeutic agents. Additionally, the potential chemical and biological diversity of peptides, despite being constructed from a limited number of amino acids, makes them well-suited for combinatorial design and guided by machine learning approaches.
Transmembrane allosteric modulators of mu opioid receptors are a promising drug candidate because they offer a unique approach to overcome the challenges of selectivity in drug design. Our strategy is to target less conserved regions in the receptor, and allosteric sites offer a solution to those challenges.
These sites are less conserved among GPCR subfamilies, meaning that allosteric modulators can be designed to bind specifically to a chosen receptor. In addition, allosteric modulators allow for the development of drugs that maintain the natural spatiotemporal signaling rhythms of orthosteric ligands, without interfering with endogenous signaling molecules.
GPCRs can be viewed as allosteric signal transduction systems, and allosteric modulation offers a platform for novel therapeutic strategies. By altering the conformation and dynamics of the receptor, allosteric drugs can increase the probability of activation or achieve increased spatial and temporal selectivity towards a chosen orthosteric ligand. Additionally, allosteric modulation can serve as a platform for preferential activation of desired intracellular signaling pathways, limiting the adverse effects of therapy due to other pathway activation.
Overall, the design of transmembrane allosteric modulators of mu opioid receptors offers a unique approach to overcome the challenge of selectivity in drug design, and is expected to present a better safety profile in overdose situations due to the weak cooperativity of the target leading to a "ceiling effect".
At mu42, we are proud to have a team of highly experienced scientists from leading Polish academic institutions. With years of expertise in the field of GPCR and opioid receptor research, our team has a deep understanding of molecular dynamics and the conformational flexibility of proteins and biomolecular systems. Our team also has a unique blend of both industry and academic experience in the research of peptides and their synthesis methods, which gives us a competitive edge in our efforts to revolutionize pain management. With such a talented and dedicated team, we are confident in our ability to bring innovative solutions to the market and make a real impact on the lives of those suffering from pain.
RSD Fund sp. z o.o. is the manager of Alternative Investment Company RDS
Fund Sp. limited liability limited partnership, as part of the
Bridge_Alfa Project "New Promised Land Seed Fund". The project is
co-financed from the European Regional Development Fund under Measure
1.3. Intelligent Development Operational Program for 2014-2020. Project
implemented as part of the National Research and Development Center
competition: BRIdge Alfa under Measure 1.3.1. Support of R&D Projects in
the preseed phase by the proof of concept funds.
The portfolio company ASI RDS Fund Sp. z o.o. S.K. managed by RDS Fund Sp. z o.o.
RSD Fund sp. z o.o. is the manager of Alternative Investment Company RDS Fund Sp. limited liability limited partnership, as part of the Bridge_Alfa Project "New Promised Land Seed Fund". The project is co-financed from the European Regional Development Fund under Measure 1.3. Intelligent Development Operational Program for 2014-2020. Project implemented as part of the National Research and Development Center competition: BRIdge Alfa under Measure 1.3.1. Support of R&D Projects in the preseed phase by the proof of concept funds.
GOAL: The aim of the project is to conduct IN VITRO and IN VIVO research on peptide allosteric modulators of the mu-opioid receptor in the treatment of chronic pain.
PROJECT NUMBER: POIR.01.03.01-00-0068/17
1. PROJECT VALUE: 1,182,380.00 PLN
2. EUROPEAN FUNDS CONTRIBUTION: 939,890.00 PLN
RESULTS: The result of the research and development work carried out will be the development of a new biological medicinal product and the submission of a patent application for the developed molecule acting in the mechanism of transmembrane positive allosteric modulator of mu opioid receptor activity, which will exhibit analgesic effects.
The solution will be implemented by introducing R&D results into their own business activities.